Golden Meditech has agreed to divest its 65.4% equity stake in China Cord Blood (CCBC) to Nanjing Yingpeng Huikang Medical Industry Investment Partnership for around RMB5.764bn ($829m).
CCBC provides cord blood collection, laboratory testing, hematopoietic stem cell processing and stem cell storage services.
Claimed to be the largest umbilical cord blood banking operator in Mainland China, CCBC has exclusive licenses in Beijing, Guangdong and Zhejiang, and minority interest in the exclusive operator in Shandong.
CCBC also owns stake in Cordlife Group, which is claimed to be the largest cord blood bank operator in Southeast Asia.
Under the deal, Golden Meditech has agreed to offer three years' performance guarantee of CCBC in favor of Nanjing Yingpeng Huikang.
Golden Meditech will use the proceedings from the deal to consolidate its healthcare services platform, expand medical and healthcare businesses, as well as engage in strategic diversification.
The deal is subject to all relevant regulatory approvals and shareholders’ approvals.
Golden Meditech carries out operations in various markets, including medical devices, cord blood storage and hospital management.
Founded by Nanjing Xinjiekou Department Store and several other institutions, Nanjing Yingpeng Huikang Medical Industry Investment Partnesrhip is a merger and acquisition fund that focuses on the medical and healthcare industry.